FDA Updates IBTROZI Label With 4-Year Response Data

FDA has approved a label update for Nuvation Bio’s IBTROZI (taletrectinib) adding more than four years of duration-of-response data in previously untreated patients with ROS1-positive non-small cell lung cancer. The supplemental approval, granted 16 September 2026, does not change the drug’s indication or its safety labeling — it is a case study in how FDA treats a label update built purely on longer follow-up of an already-approved drug.

A label update, not a new indication

IBTROZI is already approved for locally advanced or metastatic ROS1-positive NSCLC; nothing about who can be prescribed the drug changes with this filing. What changes is the evidence the label can cite. The original approval’s duration-of-response figure for TKI-naive patients was based on an earlier data cutoff with roughly 14 months less follow-up; the updated label reflects the TRUST-I trial’s more mature dataset, with a median follow-up of 51 months as of an August 2025 cutoff.

That distinction — a maturing-data supplement rather than a new-indication filing — matters for how sponsors and reviewers alike treat the submission. FDA’s review focused on whether the longer follow-up changed the safety picture or the durability claim, not on establishing efficacy in a new population. The agency found the answer was no changed safety signal and a materially stronger durability number, and approved the update well ahead of its own deadline.

The number: 49.7 months

• Trial: TRUST-I, with supporting follow-up data also referenced from TRUST-II.
• Population: TKI-naive patients with advanced ROS1-positive NSCLC.
• Updated median duration of response: 49.7 months, versus the shorter figure on the original label.
• Data cutoff: August 2025, reflecting a median follow-up of 51 months — about 14 additional months of observation over the data supporting the original approval.
• Safety: unchanged label language; no new signals identified.

Why a four-year DOR figure is a competitive detail

ROS1-positive NSCLC is a crowded but small biomarker-defined market, where oncologists weigh response durability alongside initial response rate when choosing among tyrosine kinase inhibitors for treatment-naive patients. A label that can point to a median response lasting more than four years, rather than roughly three, is a meaningful clinical-marketing distinction even though it changes nothing about the approved population or dosing. For regulatory and medical-affairs teams, it is also a reminder that a label’s numbers are not fixed at launch: sponsors can and do return with a supplement once a trial’s data simply matures further, without running a new study.

Frequently asked questions

What did FDA approve on 16 September 2026?

A supplemental New Drug Application (sNDA) for Nuvation Bio's IBTROZI (taletrectinib), a ROS1 tyrosine kinase inhibitor for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). The update adds longer-term duration-of-response (DOR) data to the label; it does not add a new indication.

What does the updated data show?

In TKI-naive patients from the TRUST-I trial, the updated label reflects a median duration of response of 49.7 months — more than four years — based on a median follow-up of 51 months and an August 2025 data cutoff. The prior label figure was based on roughly 14 months less follow-up.

Did the safety information change?

No. The approval came with no changes to the safety sections of the label, and the companies reported no new safety signals identified with the longer follow-up.

How does this compare to FDA's review timeline?

The sNDA was approved roughly four months ahead of its PDUFA target action date in September 2026.